Genesis Therapeutics Secures $200M Series B Funding for AI Drug Discovery and Clinical Testing
Genesis Therapeutics has raised $200 million in Series B financing, co-led by Andreessen Horowitz and an anonymous life science investor. The startup, which utilizes artificial intelligence to design small molecule drugs, plans to use the funds to further develop its AI technologies, expand its pipeline, and advance its first computer-generated drugs into clinical studies.